Drug intelligence / Profile preview

SV-IO-002

Development stage: Preclinical
Lead developer: SunVax mRNA Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intratumoral

Overview

SV-IO-002 is an mRNA-based immuno-oncology therapeutic candidate being developed by SunVax mRNA Therapeutics. Currently in preclinical development (preclinical candidate stage), the drug is designed for the treatment of solid tumors, with potential applications in hematologic neoplasms and pancreatic ductal carcinoma. SV-IO-002 leverages SunVax's proprietary lipid nanoparticle (LNP) delivery technology and self-amplifying mRNA (samRNA) platform to deliver therapeutic payloads. The specific molecular target and mechanism of action for SV-IO-002 have not been publicly disclosed.

Beyond the preview

Go deeper on SV-IO-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SV-IO-002.

Explore the full profile